Haleon’s recent weakness provides buying opportunity, says Argus

Argus keeps a Buy rating and $10 price target on Haleon but notes that the stock’s recent weakness offers a buying opportunity. The company stands to benefit as it aims to take advantage of emerging secular trends, such as the growing popularity of preventive medicine and the increasing shift from prescription to over-the-counter medications, the analyst tells investors in a research note. Haleon is also supported by its market-leading brand names that include Advil, Theraflu and Centrum, the firm added.